Sugi Predict

Sugi Predict / Targets / F9

F9

Coagulation factor IX · P00740 · F9 on Sugi Atlas →

34,333 patent compounds predicted against F9, 17,283 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL390032 SCHEMBL390032 0.55 13/20
SCHEMBL392690 SCHEMBL392690 0.51 13/20
SCHEMBL393253 SCHEMBL393253 0.51 13/20
SCHEMBL393106 SCHEMBL393106 0.51 10/20
SCHEMBL395016 SCHEMBL395016 0.51 10/20
SCHEMBL335322 SCHEMBL335322 0.64 9/20
SCHEMBL121774 SCHEMBL121774 0.63 9/20
SCHEMBL149464 SCHEMBL149464 0.58 9/20
SCHEMBL335522 SCHEMBL335522 0.53 8/20
SCHEMBL335786 SCHEMBL335786 0.51 8/20
SCHEMBL335793 SCHEMBL335793 0.50 8/20
SCHEMBL335882 SCHEMBL335882 0.50 8/20
SCHEMBL336190 SCHEMBL336190 0.50 8/20
SCHEMBL336483 SCHEMBL336483 0.54 7/20
SCHEMBL335863 SCHEMBL335863 0.51 7/20
SCHEMBL335253 SCHEMBL335253 0.50 7/20
SCHEMBL335724 SCHEMBL335724 0.50 7/20
SCHEMBL335697 SCHEMBL335697 0.49 7/20
SCHEMBL335640 SCHEMBL335640 0.56 6/20
SCHEMBL121331 SCHEMBL121331 0.67 5/20

Clinical trials — most relevant to F9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal PHASE4COMPLETED
Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX PHASE4COMPLETED
Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study) PHASE4RECRUITING
An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A. PHASE3COMPLETED
BAX 326 Surgery Study in Hemophilia B Patients PHASE3COMPLETED
A Study Investigating Treatment Factor X in People With Factor X Deficiency PHASE3COMPLETED
A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B PHASE3COMPLETED
Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B PHASE3COMPLETED
rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study PHASE3COMPLETED
A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A PHASE3ACTIVE_NOT_RECRUITING
HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients PHASE3COMPLETED
Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B PHASE2COMPLETED
Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency PHASE1/PHASE2COMPLETED
Fiix-prothrombin Time for Monitoring Warfarin PHASE2COMPLETED
Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State PHASE1COMPLETED
Safety and Dosing Evaluation of REG1 Anticoagulation System PHASE1COMPLETED
Lentiviral FIX Gene Therapy PHASE1RECRUITING
Patterns of Hemophilia Care in Assiut Children Patients nanUNKNOWN
Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19 nanNO_LONGER_AVAILABLE
A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy nanACTIVE_NOT_RECRUITING
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders nanRECRUITING
Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem nanCOMPLETED
Learning to Live With Non-severe Haemophilia nanCOMPLETED
Cross-sectional Study on Prevalence of Coagulation Factors Deficiency in Assiut University Children Hospital nanUNKNOWN
Effects of Emicizumab Treatment in Patients With Hemophilia A nanNOT_YET_RECRUITING
Factor XIII Activity in Gastrointestinal Bleedings nanCOMPLETED
Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles nanCOMPLETED
Quality of Life in Hemophilia by Clinical Scoring System (FISH)Score nanUNKNOWN
Observatory of Patients With Haemophilia B Treated by IdElvion® nanACTIVE_NOT_RECRUITING
Diagnostic Accuracy Study of a Point-of-Care Test for Coagulation Function nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a F9 binder may also engage these)

ProteinNameSimilarity
Q95ND7 — 1.000 Q95ND7 →
P00741 — 1.000 P00741 →
P16294 — 1.000 P16294 →
P19540 — 1.000 P19540 →
Q6SA95 — 1.000 Q6SA95 →
P16293 — 1.000 P16293 →
Q1L659 — 0.998 Q1L659 →
O88947 — 0.998 O88947 →
P16296 — 0.998 P16296 →
Q58L94 — 0.997 Q58L94 →
Q58L93 — 0.997 Q58L93 →
Q804X6 — 0.997 Q804X6 →
B5G6G5 — 0.997 B5G6G5 →
P83370 — 0.997 P83370 →
A6MFK7 — 0.996 A6MFK7 →
Q1L658 — 0.996 Q1L658 →
P82807 — 0.996 P82807 →
Q63207 — 0.995 Q63207 →
Q58L95 — 0.995 Q58L95 →
P81428 — 0.995 P81428 →
P29598 — 0.995 P29598 →
F10 Coagulation factor X 0.994 landscape →
P33587 — 0.993 P33587 →
P31394 — 0.993 P31394 →
P25155 — 0.992 P25155 →
Q56VR3 — 0.992 Q56VR3 →
P49150 — 0.992 P49150 →
Q58L96 — 0.992 Q58L96 →
Q14C59 — 0.990 Q14C59 →
P18292 — 0.990 P18292 →